The CDK 4/6 inhibitor ribociclib has activity in the treatment of inoperable desmoid tumor. A case report

Santti, Kirsi; Beule, Annette; Rönty, Mikko; Ihalainen, Hanna; Tarkkanen, Maija; Blomqvist, Carl

doi:10.1080/0284186x.2019.1588992

Search citation statements

Order By: Relevance

Paper Sections

Select...

Cdk4/6 Inhibitors Use In Crc1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

2021

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, used in combination with 5-FU, it increases significantly p53 phosphorylation. Ribociclib treatment was also used in a study case on a young female diagnosed with desmoid tumors (DT) ( Santti et al, 2019 ). She underwent colectomy and various other surgeries to remove the tumors, as well as irradiation therapy.…”

Section: Cdk4/6 Inhibitors Use In Crcmentioning

confidence: 99%

Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment

Thoma

Waldner

2021

Front. Pharmacol.

View full text Add to dashboard Cite

Cyclin-dependent kinases (CDKs) are key players in cell cycle regulation. So far, more than ten CDKs have been described. Their direct interaction with cyclins allow progression through G1 phase, transitions to S and G2 phase and finally through mitosis (M). While CDK activation is important in cell renewal, its aberrant expression can lead to the development of malignant tumor cells. Dysregulations in CDK pathways are often encountered in various types of cancer, including all gastrointestinal (GI) tract tumors. This prompted the development of CDK inhibitors as novel therapies for cancer. Currently, CDK inhibitors such as CDK4/6 inhibitors are used in pre-clinical studies for cancer treatment. In this review, we will focus on the therapeutic role of various CDK inhibitors in colorectal cancer, with a special focus on the CDK4/6 inhibitors.

show abstract

Section: Cdk4/6 Inhibitors Use In Crcmentioning

confidence: 99%